文献速递肝病

自身免疫性肝炎的个体化治疗:硫嘌呤代谢物监测可提高生化应答率

Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates.
PubMed 文献 · J Hepatol · 2021-04-16

该回顾性匹配队列研究纳入1999-2019年King's College的214例AIH患者,其中109例监测硫嘌呤代谢物,105例按体重给药。结果显示代谢物监测组6个月生化应答率显著高于对照组(77% vs 60%,p=0.008),且TGN水平在治疗范围(225-450 pmol/8x108红细胞)内与更稳定的疾病相关(p<0.0001)。亚治疗TGN水平患者生化应答率与治疗范围患者相当(75% vs 81%,p=0.589)但不良反应更少(44% vs 86%,p=0.0002)。

要点

  • 代谢物监测组6个月生化应答率77%,显著高于体重给药组的60%(p=0.008)。
  • TGN水平在225-450 pmol/8x108红细胞内与6个月内更稳定疾病显著相关(p<0.0001)。
  • 亚治疗TGN水平患者生化应答率与治疗范围相当,但不良反应更少(44% vs 86%,p=0.0002)。

核心结论

  • 基于硫嘌呤代谢物监测的个体化治疗策略可优化AIH治疗方案,在维持生化应答的同时减少不良反应。

研究设计与样本

  • 回顾性匹配队列研究,纳入1999-2019年King's College的214例AIH患者,109例监测代谢物,105例按体重给药无监测。

主要发现

  • 代谢物监测组6个月生化应答率77%,体重给药组60%,差异显著(p=0.008)。
  • 按医生是否监测代谢物分析,6个月生化应答率84% vs 64%(p=0.016)。
  • 生化应答者TGN水平在225-450 pmol/8x108红细胞内的比例显著高于未应答或失去应答者(40% vs 13%,p<0.0001)。
  • TGN水平在预设治疗范围内预测6个月内更稳定疾病(p<0.0001)。
  • 亚治疗TGN水平(75-225 pmol/8x108红细胞)患者生化应答率与治疗范围患者相当(75% vs 81%,p=0.589),但不良反应更少(44% vs 86%,p=0.0002)。

关键数值与推荐

  • TGN治疗范围定义为225-450 pmol/8x108红细胞。
  • 亚治疗TGN水平定义为75-225 pmol/8x108红细胞。

临床怎么用

  • 对AIH维持治疗患者可考虑监测硫嘌呤代谢物水平以个体化调整剂量。
  • TGN水平在治疗范围(225-450 pmol/8x108红细胞)内与更高生化应答率和更稳定疾病相关。
  • 亚治疗TGN水平(75-225 pmol/8x108红细胞)可在维持生化应答的同时减少不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with autoimmune hepatitis (AIH) usually receive maintenance therapy with thiopurines, such as azathioprine (AZA) or mercaptopurine. Genetic polymorphisms in AZA metabolism can lead to variations in thioguanine nucleotide (TGN) and 6-methylmercaptopurine, both of which can cause adverse drug reactions (ADRs). In inflammatory bowel disease, a therapeutic TGN range (225-450 pmol/8x108 erythrocytes) has been identified to optimise effectiveness. We evaluated the benefits of a personalised medicine approach to thiopurine dosing, in comparison to standard weight-based dosing. METHODS: A retrospective matched cohort study of 214 patients with AIH who were seen at King's College between 1999-2019 was performed. Metabolite levels were measured in 109 patients. The control group included 105 patients on weight-based thiopurine dosing with no metabolite monitoring. RESULTS: Biochemical response (BR) occurred more frequently at 6-month follow-up in patients with metabolite monitoring compared to those on a weight-based regimen (77% vs. 60%, p = 0.008). This remained true with data analysis based on clinicians who measure metabolites and those who do not (BR at 6 months: 84% vs. 64%, p = 0.016). Patients with BR had TGN levels within the therapeutic range of 225-450 pmol/8x108 erythrocytes significantly more often than those who failed to achieve or lost BR (40% vs. 13%, p <0.0001). Moreover, TGN levels within the pre-defined therapeutic range predicted more stable disease within 6 months of testing compared to levels outside the range (p <0.0001). A high proportion of patients with sub-therapeutic TGN levels (75-225 pmol/8x108 erythrocytes) remained in BR (75% vs. 81%, p = 0.589) with fewer ADRs (44% vs. 86%, p = 0.0002) when compared to patients with therapeutic TGN levels. CONCLUSION: A strategy of personalised medicine using metabolite levels can optimise treatment regimens in AIH, resulting in fewer ADRs whilst maintaining BR. LAY SUMMARY: This study looked to see if measuring the breakdown products of a medication used in autoimmune hepatitis increases the chances of gaining good control of the disease, when compared to a group of patients who were on a dose of this medication based on their weight. A group of 214 patients with autoimmune hepatitis were split into 2 groups: roughly half had their medication dose adjusted according to measurements of breakdown products in the blood, whilst the other half received their weight-based dose as normal. The results confirmed that using a personalised approach and checking drug breakdown products resulted in fewer side effects and potentially improved control of disease.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Candels LS, Rahim MN, Shah S, et al. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol. 2021. PMID: 33872691. doi:10.1016/j.jhep.2021.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。